The burgeoning optimism surrounding classic psychedelics as revolutionary treatments for depression may need a recalibration, as emerging data suggests their…
Read More
Lilly offers up to $3.8 billion for AtaiBeckley in bet on ‘God molecule’ found in toad venom
Eli Lilly has formally agreed to acquire AtaiBeckley for a substantial sum, comprising $2.8 billion upfront and an additional $1…
Read More
Diabetes to MASH: the specimens behind GLP-1’s widening roster
The therapeutic landscape for metabolic diseases has been irrevocably reshaped by the emergence of GLP-1 receptor agonists, a class of…
Read More
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
Over a decade ago, the American Society of Clinical Oncology (ASCO) initiated a groundbreaking endeavor with the launch of CancerLinQ,…
Read More
Pens to Pills: The Transformative Era of Oral GLP-1 Receptor Agonists in Drug Discovery and Patient Care
The pharmaceutical landscape for metabolic diseases has reached a pivotal inflection point, marked by the recent approval of the first…
Read More
How most-favored-nation pricing is reshaping generic drug economics, according to Dr. Reddy’s finance director
The United States, long an outlier in global pharmaceutical pricing, is undergoing a profound transformation in its drug cost landscape,…
Read More
Insuring the trip: an underwriter on what it will take for approved psilocybin can become a real business
More than five decades after the Controlled Substances Act, signed by President Richard Nixon in 1970, categorized psilocybin as a…
Read More
PharmSci 360 2026 heads to New Orleans this October
The American Association of Pharmaceutical Scientists (AAPS) is set to convene its premier annual gathering, PharmSci 360, from October 25…
Read More
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
At its recent annual Science Day, biotechnology giant Moderna signaled a profound strategic expansion beyond its highly successful infectious disease…
Read More
Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness
For millions worldwide, the diagnosis of actinic keratosis (AK) marks the beginning of a challenging journey to prevent skin cancer.…
Read MoreYOU MAY HAVE MISSED
